You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameFluocinonide
Accession NumberDB01047  (APRD00978)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionA topical glucocorticoid used in the treatment of eczema. [PubChem]
Structure
Thumb
Synonyms
Fluocinonide
Fluocinonido
Fluocinonidum
Lidex
Vanos
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluocinonidesolution.5 mg/mLtopicalCounty Line Pharmaceuticals, LLC2014-02-28Not applicableUs
Fluocinonidecream.5 mg/gtopicalA S Medication Solutions Llc1984-06-26Not applicableUs
Fluocinonidecream.5 mg/mLtopicalGolden State Medical Supply, Inc.1984-06-26Not applicableUs
Fluocinonidecream.5 mg/gtopicalLake Erie Medical DBA Quality Care Products LLC1984-06-26Not applicableUs
Fluocinonidecream.5 mg/gtopicalA S Medication Solutions Llc1984-06-26Not applicableUs
Fluocinonidecream1 mg/gtopicalOceanside Pharmaceuticals2014-01-06Not applicableUs
Fluocinonidecream.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1984-06-26Not applicableUs
Fluocinonidecream.5 mg/gtopicalPhysicians Total Care, Inc.1984-06-26Not applicableUs
Fluocinonidecream.5 mg/gtopicalPreferred Pharmaceuticals, Inc.2014-05-21Not applicableUs
Fluocinonidecream.5 mg/gtopicalA S Medication Solutions Llc1984-06-26Not applicableUs
Lidemol 0.05%emulsion; cream.05 %topicalSyntex Inc.1979-12-311996-09-30Canada
Lidemol Emollient Cream 0.05%cream0.05 %topicalValeant Canada Lp/valeant Canada s.e.c.1995-12-31Not applicableCanada
Lidexointment0.05 %topicalValeant Canada Lp/valeant Canada s.e.c.1995-12-31Not applicableCanada
Lidexgel0.05 %topicalValeant Canada Lp/valeant Canada s.e.c.1995-12-31Not applicableCanada
Lidexcream0.05 %topicalValeant Canada Lp/valeant Canada s.e.c.1996-12-31Not applicableCanada
Lidex Cream Mild 0.01%cream0.01 %topicalMedicis Canada Ltd.1972-12-311998-09-25Canada
Lidex Ointment Mild 0.01%ointment0.01 %topicalMedicis Canada Ltd.1973-12-311998-09-25Canada
Lidex Ont 0.05%ointment.05 %topicalSyntex Inc.1973-12-311996-09-30Canada
Lyderm Cream 0.05%cream0.05 %topicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1988-12-31Not applicableCanada
Lyderm Gel 0.05%gel0.05 %topicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1998-04-27Not applicableCanada
Lyderm Ointment 0.05%ointment0.05 %topicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1999-10-15Not applicableCanada
Lydonide Cream 0.05%cream.05 %topicalTechnilab Pharma Inc.1996-07-302004-08-03Canada
Lydonide Emollient Cream 0.05%cream.05 %topicalTechnilab Pharma Inc.1996-07-302004-08-03Canada
Lydonide Ointment 0.05%ointment.05 %topicalTechnilab Pharma Inc.1996-07-302004-08-03Canada
Tiamol Cream 0.05%cream0.05 %topicalTaropharma, A Division Of Taro Pharmaceuticals Inc.1983-12-31Not applicableCanada
Topactin Cream 0.05% U.S.P.cream0.05 %topicalPaladin Labs Inc1991-12-31Not applicableCanada
Topactin Emollient Cream 0.05%cream0.5 mgtopicalPaladin Labs Inc1991-12-31Not applicableCanada
Topsyn 0.05%jelly.5 mgtopicalSyntex Inc.1973-12-311996-09-30Canada
Vanoscream1 mg/gtopicalPhysicians Total Care, Inc.2010-11-30Not applicableUs
Vanoscream1 mg/gtopicalMedicis Pharmaceutical Corp2006-03-13Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Fluocinonidegel.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1994-12-30Not applicableUs
Fluocinonidegel.5 mg/gtopicalH.J. Harkins Company, Inc.2011-01-20Not applicableUs
Fluocinonidecream.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2004-06-23Not applicableUs
Fluocinonidecream.5 mg/gtopicalProficient Rx LP1984-06-26Not applicableUs
Fluocinonidecream1 mg/gtopicalPerrigo New York Inc2014-01-14Not applicableUs
Fluocinonidecream.5 mg/gtopicalTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Fluocinonidegel.5 mg/gtopicalPhysicians Total Care, Inc.2004-05-20Not applicableUs
Fluocinonidegel.5 mg/gtopicalG&W Laboratories, Inc.2015-12-18Not applicableUs
Fluocinonidesolution.5 mg/mLtopicalTaro Pharmaceuticals U.S.A., Inc.1996-12-31Not applicableUs
Fluocinonidesolution.5 mg/mLtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1995-02-27Not applicableUs
Fluocinonidecream.5 mg/gtopicalCentral Texas Community Health Centers1990-09-30Not applicableUs
Fluocinonideointment.5 mg/gtopicalA S Medication Solutions Llc1999-06-30Not applicableUs
Fluocinonidecream1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2014-07-14Not applicableUs
Fluocinonidecream.5 mg/gtopicalTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Fluocinonidecream.5 mg/gtopicalMed Vantx, Inc.1990-09-30Not applicableUs
Fluocinonidecream.5 mg/gtopicalMedsource Pharmaceuticals1990-09-30Not applicableUs
Fluocinonideointment.5 mg/gtopicalPhysicians Total Care, Inc.1994-11-22Not applicableUs
Fluocinonidecream.5 mg/gtopicalSTAT Rx USA LLC1994-10-17Not applicableUs
Fluocinonidegel.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1997-07-29Not applicableUs
Fluocinonidecream.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1994-10-17Not applicableUs
Fluocinonidecream1 mg/gtopicalPharmaceutica North America, Inc2016-02-02Not applicableUs
Fluocinonidesolution.5 mg/mLtopicalActavis Pharma, Inc.2013-05-12Not applicableUs
Fluocinonidecream.5 mg/gtopicalPhysicians Total Care, Inc.1993-12-08Not applicableUs
Fluocinonideointment.5 mg/gtopicalTeva Pharmaceuticals USA Inc1992-05-01Not applicableUs
Fluocinonidecream1 mg/gtopicalGlenmark Pharmaceuticals Inc., Usa2014-07-14Not applicableUs
Fluocinonidecream.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1989-01-19Not applicableUs
Fluocinonideointment.5 mg/mLtopicalGolden State Medical Supply, Inc.1997-07-29Not applicableUs
Fluocinonidecream.5 mg/gtopicalRebel Distributors Corp1984-06-26Not applicableUs
Fluocinonidecream.5 mg/gtopicalPreferred Pharmaceuticals Inc.2016-03-02Not applicableUs
Fluocinonidecream1 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2014-07-14Not applicableUs
Fluocinonideointment.5 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.1997-08-26Not applicableUs
Fluocinonidecream.5 mg/gtopicalActavis Pharma, Inc.2014-04-09Not applicableUs
Fluocinonidesolution.5 mg/mLtopicalPhysicians Total Care, Inc.1993-05-28Not applicableUs
Fluocinonideointment.5 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.1999-06-30Not applicableUs
Fluocinonidegel.5 mg/gtopicalTeva Pharmaceuticals USA Inc1990-09-302016-03-31Us
Fluocinonidecream.5 mg/gtopicalPreferred Pharmaceuticals, Inc.2014-07-30Not applicableUs
Fluocinonidesolution.5 mg/mLtopicalGolden State Medical Supply, Inc.1996-12-31Not applicableUs
Fluocinonideointment.5 mg/gtopicalRebel Distributors Corp2011-01-20Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
FluonexNot Available
LidexMedicis
Lidex-EMedicis
LonideNot Available
LydermTaro
MetosynBioglan
TopsyminNot Available
TopsynSyntex
Brand mixtures
NameLabellerIngredients
Lidecomb CreamMedicis Canada Ltd.
SaltsNot Available
Categories
UNII2W4A77YPAN
CAS number356-12-7
WeightAverage: 494.5249
Monoisotopic: 494.211609788
Chemical FormulaC26H32F2O7
InChI KeyInChIKey=WJOHZNCJWYWUJD-IUGZLZTKSA-N
InChI
InChI=1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
IUPAC Name
2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-8-yl]-2-oxoethyl acetate
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@]([H])(F)C5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(OC(C)(C)O2)C(=O)COC(C)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 6-halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Acetate salt
  • Cyclic alcohol
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationA topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
PharmacodynamicsFluocinonide is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort. [Wikipedia]
Mechanism of actionFluocinonide is a potent glucocorticoid steroid used topically as anti-inflammatory agent for the treatment of skin disorders such as eczema. It relieves itching, redness, dryness, crusting, scaling, inflammation, and discomfort. Fluocinonide binds to the cytosolic glucocorticoid receptor. After binding the receptor the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing the increase in expression of specific target genes. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Specifically glucocorticoids induce lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing the phospholipase A2 from coming into contact with its substrate arachidonic acid. This leads to diminished eicosanoid production. Cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. In another words, the two main products in inflammation Prostaglandins and Leukotrienes are inhibited by the action of Glucocorticoids. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion, emigration, chemotaxis, phagocytosis, respiratory burst and the release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, chemokines etc.) from neutrophils, macrophages and mastocytes. Additionally the immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Like other glucocorticoid agents Fluocinolone acetonide acts as a physiological antagonist to insulin by decreasing glycogenesis (formation of glycogen). It also promotes the breakdown of lipids (lipolysis), and proteins, leading to the mobilization of extrahepatic amino acids and ketone bodies. This leads to increased circulating glucose concentrations (in the blood). There is also decreased glycogen formation in the liver.
Related Articles
AbsorptionThe extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. In general, percutaneous absorption is minimal.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects may include acne-like eruptions, burning, dryness, excessive hair growth, infection of the skin, irritation, itching, lack of skin color, prickly heat, skin inflammation, skin loss or softening, stretch marks
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9823
Blood Brain Barrier+0.981
Caco-2 permeable-0.5804
P-glycoprotein substrateSubstrate0.7813
P-glycoprotein inhibitor IInhibitor0.8103
P-glycoprotein inhibitor IINon-inhibitor0.5782
Renal organic cation transporterNon-inhibitor0.8178
CYP450 2C9 substrateNon-substrate0.8667
CYP450 2D6 substrateNon-substrate0.8951
CYP450 3A4 substrateSubstrate0.7219
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9482
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8455
Ames testNon AMES toxic0.7768
CarcinogenicityNon-carcinogens0.9166
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1492 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9835
hERG inhibition (predictor II)Non-inhibitor0.6907
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Creamtopical.5 mg/g
Creamtopical.5 mg/mL
Creamtopical1 mg/g
Geltopical.5 mg/g
Ointmenttopical.5 mg/mL
Ointmenttopical.5 mg/g
Solutiontopical.5 mg/mL
Creamtopical
Emulsion; creamtopical.05 %
Creamtopical0.01 %
Ointmenttopical0.01 %
Ointmenttopical.05 %
Geltopical0.05 %
Ointmenttopical0.05 %
Creamtopical.05 %
Creamtopical0.05 %
Creamtopical0.5 mg
Jellytopical.5 mg
Prices
Unit descriptionCostUnit
Vanos 0.1% Cream 60 gm Tube275.75USD tube
Fluocinonide powder176.0USD g
Vanos 0.1% Cream 30 gm Tube155.34USD tube
Fluocinonide 0.05% Ointment 60 gm Tube50.96USD tube
Fluocinonide 0.05% Gel 60 gm Tube50.78USD tube
Fluocinonide-E 0.05% Cream 60 gm Tube47.84USD tube
Fluocinonide 0.05% Gel 30 gm Tube30.1USD tube
Fluocinonide 0.05% Ointment 30 gm Tube28.61USD tube
Fluocinonide-E 0.05% Cream 30 gm Tube28.6USD tube
Fluocinonide 0.05% Solution 60ml Bottle27.23USD bottle
Fluocinonide 0.05% Cream 60 gm Tube22.71USD tube
Fluocinonide 0.05% Solution 20ml Bottle21.99USD bottle
Fluocinonide 0.05% Ointment 15 gm Tube21.88USD tube
Fluocinonide 0.05% Gel 15 gm Tube21.85USD tube
Fluocinonide-E 0.05% Cream 15 gm Tube20.18USD tube
Fluocinonide 0.05% Cream 30 gm Tube13.54USD tube
Fluocinonide 0.05% Cream 15 gm Tube11.99USD tube
Vanos 0.1% cream4.13USD g
Lidex 0.05% cream3.57USD g
Fluocinonide-e 0.05% cream1.33USD g
Fluocinonide 0.05% cream0.6USD g
Fluocinonide-emol 0.05% cream0.4USD g
Lyderm 0.05 % Gel0.38USD g
Lyderm 0.05 % Ointment0.37USD g
Lyderm 0.05 % Cream0.29USD g
Tiamol 0.05 % Emollient Cream0.27USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6765001 No2001-12-212021-12-21Us
US7220424 No2003-01-072023-01-07Us
US7794738 No2002-09-112022-09-11Us
US8232264 No2003-03-092023-03-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point309 °CPhysProp
water solubility4.74 mg/LNot Available
logP3.19HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0168 mg/mLALOGPS
logP2.93ALOGPS
logP2.05ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)13.55ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity120.56 m3·mol-1ChemAxon
Polarizability49.12 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

US. Patent 3,197,469.

General ReferencesNot Available
External Links
ATC CodesD07CC05D07AC08C05AA11
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (818 KB)
MSDSDownload (75.1 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Fluocinonide.
AldesleukinFluocinonide may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Fluocinonide can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Fluocinonide can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Fluocinonide.
AmiodaroneThe serum concentration of Fluocinonide can be increased when it is combined with Amiodarone.
Amphotericin BFluocinonide may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Fluocinonide can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Fluocinonide can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Fluocinonide.
BazedoxifeneThe serum concentration of Fluocinonide can be increased when it is combined with Bazedoxifene.
BendroflumethiazideFluocinonide may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Fluocinonide.
Bismuth SubcitrateThe bioavailability of Fluocinonide can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Fluocinonide can be increased when it is combined with Boceprevir.
BumetanideFluocinonide may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Fluocinonide.
Calcium carbonateThe bioavailability of Fluocinonide can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Fluocinonide can be decreased when it is combined with Carbamazepine.
CeritinibFluocinonide may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Fluocinonide can be increased when it is combined with Ceritinib.
ChlorothiazideFluocinonide may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Fluocinonide can be increased when it is combined with Chlorotrianisene.
ChlorthalidoneFluocinonide may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Fluocinonide can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Fluocinonide can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Fluocinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Fluocinonide can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Fluocinonide.
CoumaphosThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Coumaphos.
DarunavirThe serum concentration of Fluocinonide can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Dichlorvos.
DienestrolThe serum concentration of Fluocinonide can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Fluocinonide can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Fluocinonide.
DihydrotestosteroneFluocinonide may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Edrophonium.
EnzalutamideThe serum concentration of Fluocinonide can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Fluocinonide can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Fluocinonide can be increased when it is combined with Estriol.
EstroneThe serum concentration of Fluocinonide can be increased when it is combined with Estrone.
Etacrynic acidFluocinonide may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Fluocinonide can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Fenthion.
FluoxymesteroneFluocinonide may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Fluocinonide can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fluocinonide can be decreased when it is combined with Fosphenytoin.
FurosemideFluocinonide may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Fluocinonide can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Fluocinonide.
HexestrolThe serum concentration of Fluocinonide can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Fluocinonide.
HydrochlorothiazideFluocinonide may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazideFluocinonide may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Fluocinonide can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Fluocinonide.
IndapamideFluocinonide may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Fluocinonide can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Fluocinonide.
ItraconazoleThe serum concentration of Fluocinonide can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Fluocinonide can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Fluocinonide can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Fluocinonide can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Fluocinonide can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Fluocinonide can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Fluocinonide can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Fluocinonide.
MestranolThe serum concentration of Fluocinonide can be increased when it is combined with Mestranol.
MethyclothiazideFluocinonide may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteroneFluocinonide may increase the fluid retaining activities of Methyltestosterone.
MetolazoneFluocinonide may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Fluocinonide can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Minaprine.
MitotaneThe serum concentration of Fluocinonide can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Fluocinonide.
NefazodoneThe serum concentration of Fluocinonide can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Fluocinonide can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Neostigmine.
NevirapineThe serum concentration of Fluocinonide can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Nicorandil.
OxandroloneFluocinonide may increase the fluid retaining activities of Oxandrolone.
OxymetholoneFluocinonide may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Fluocinonide can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Fluocinonide can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Fluocinonide.
PhenytoinThe serum concentration of Fluocinonide can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Physostigmine.
PiretanideFluocinonide may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Fluocinonide can be increased when it is combined with Polyestradiol phosphate.
PolythiazideFluocinonide may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Fluocinonide can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Fluocinonide can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Pyridostigmine.
QuinestrolThe serum concentration of Fluocinonide can be increased when it is combined with Quinestrol.
QuinethazoneFluocinonide may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Fluocinonide.
RifabutinThe serum concentration of Fluocinonide can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Fluocinonide can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Fluocinonide can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Fluocinonide can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Fluocinonide.
SaquinavirThe serum concentration of Fluocinonide can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Fluocinonide.
StanozololFluocinonide may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Fluocinonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Fluocinonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Fluocinonide.
TelaprevirThe serum concentration of Fluocinonide can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Fluocinonide can be increased when it is combined with Telithromycin.
TestosteroneFluocinonide may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Fluocinonide can be increased when it is combined with Tibolone.
TorasemideFluocinonide may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Trichlorfon.
TrichlormethiazideFluocinonide may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Tubocurarine.
VoriconazoleThe serum concentration of Fluocinonide can be increased when it is combined with Voriconazole.
WarfarinFluocinonide may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Fluocinonide can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Jessop S, Whitelaw D, Jordaan F: Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2001;(1):CD002954. [PubMed:11279785 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Wnt-protein binding
Specific Function:
G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor patched is thought to prevent normal inhibition by patched of smoothened (SMO). Required for the accumulation of KIF7 and GLI3 in the cilia.
Gene Name:
SMO
Uniprot ID:
Q99835
Molecular Weight:
86395.95 Da
References
  1. Wang J, Lu J, Bond MC, Chen M, Ren XR, Lyerly HK, Barak LS, Chen W: Identification of select glucocorticoids as Smoothened agonists: potential utility for regenerative medicine. Proc Natl Acad Sci U S A. 2010 May 18;107(20):9323-8. doi: 10.1073/pnas.0910712107. Epub 2010 May 3. [PubMed:20439738 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:26